Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

August 10, 2026

To Listing / Compliance Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001	To Listing / Compliance Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051
BSE CODE: 543329	**NSE SYMBOL: WINDLAS**

Dear Sir/ Madam.

Sub: <u>Press Release</u>

Please find attached herewith press release titled "Windlas Biotech Limited Reports its Q1 FY27 Financial Results".

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited
ANANTA NARAYAN PANDA
2026.08.10 16:01:42 +05'30'
11.0.10

Ananta Narayan Panda
Company Secretary & Compliance Officer

Encl: as above

Press Release

Windlas Biotech Limited Reports its Q1 FY27 Financial Results

- ✓ **14th consecutive quarter** of record Revenue, Rs 248 crores (Q1FY27)
- ✓ Adjusted EBITDA recorded at Rs 34 crores; growth of **26% YoY** (Q1FY27)
- ✓ Adjusted PAT growth of **37% YoY** to Rs 25 crores (Q1FY27)
- ✓ Successfully completed **Rs 47 crore** share buyback without Promotor's participation
- ✓ Dividend paid **Rs 13 crores** (Rs 6.3 per share) for FY26
- ✓ Reported EPS of Rs 8.46

Monday, 10th August 2026, Gurugram: Windlas Biotech Limited, one of the leading players in the domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, reported its unaudited financials for the quarter ended June 30, 2026.

Consolidated Highlights:

Q1FY27 Highlights:

- ✓ **Revenue from operations** stood at **Rs 248 crores** as against **Rs 210 crores**, a growth of **18% YoY**
- ✓ **Adjusted EBITDA** stood at **Rs 34 crores** as against **Rs 27 crores**, a growth of **26% YoY**. **Adjusted EBITDA Margin** came in at **13.6%**
- ✓ **Adjusted PAT** stood at **Rs 25 crores** as against **Rs 18 crores**, a growth of **37% YoY**. **PAT Margin** came in at **10%**

Note:

1) Adjusted EBITDA & Margin and PAT & Margin are excluding the impact of Non-cash ESOP expenses of Rs 7.16 Cr.

2) Reported EBITDA stood at Rs 27 crores. Reported PAT stood at Rs 18 crores.

Vertical Performance Update:

Particulars (In Rs. Crores)	Q1FY27	Q1FY26	Y-o-Y
Generic Formulations CDMO	207	160	29%
Trade Generics & Institutional	30	44	-32%
Exports	11	6	79%

Generic Formulations CDMO Vertical Highlights

- Q1FY26 revenue for the CDMO vertical stood at Rs 207 crores, up 29% YoY.
- CDMO vertical contributed approximately 84% for Q1FY27 to the consolidated revenue.

Trade Generics & Institutional Vertical Highlights

- Q1FY27 revenue for the Trade Generics & Institutional vertical stood at Rs 30 crores, down -32% YoY.
- Trade Generics vertical contributed approximately 12% for Q1FY27 to the consolidated revenue.

Exports Vertical Highlights

- Q1FY27 revenue for the Exports vertical stood at Rs 11 crores, up 79% YoY.
- Exports vertical contributed approximately 4% for Q1FY27 to the consolidated revenue.

Commenting on the results Mr. Hitesh Windlass, Managing Director – Windlas Biotech said,

"The Indian Pharmaceutical Market (IPM) witnessed a volume growth of 3.4% in Q1 FY27, reflecting a steady yet measured industry environment. Against this backdrop, Windlas Biotech continued its growth trajectory, delivering its highest-ever quarterly revenue of ₹248 crore, representing 18% YoY growth. This performance underscores the strength and resilience of our diversified business model, our operational excellence, and the trust our customers place in us.

We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities. Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectiveness of our strategic investments.

We remain focused on creating sustainable value through disciplined execution, talent development, client diversification, capability enhancement, and expansion across dosage forms. I would like to thank our customers, partners and employees, shareholders for their continued trust and support.**"**

Adding further, Ms. Komal Gupta, CEO & CFO - Windlas Biotech said,

"We have started FY27 with a positive note by extending our record revenue streak to 14 consecutive quarters with 18% YoY growth to Rs 248 crore. Consistent with our focus on long-term shareholders value creation, in Q1 FY27 the company also completed ₹47 crore buyback in which promoters did not participate and declaration of FY26 dividend ₹13 crore (₹6.30 per equity share).

Excluding the impact of ESOP expenses (₹7.2 Crore) which are non-cash in nature, our EBITDA grew 26% YoY to ₹34 crore, PBT and PAT grew 27% and 37% YoY to ₹30 crore and ₹25 crore respectively, reflecting our continued focus on improving operational leverage. If we take into account Non-cash ESOP expenditure (₹7.2 crore), the company reported EBITDA ₹27 crore, PBT ₹23 crore and PAT ₹18 crore. For Q1 FY27 Earnings Per Share (EPS) has improved to ₹ 8.46.

Our Generic Formulations CDMO vertical delivered 29% YoY revenue growth to ₹207 crore, driven by customer expansion, deeper customer engagement, and new product launches. The Trade Generics & Institutional vertical reported revenue of ₹30 crore, following the discontinuation of codeine-based products. As we expand the portfolio with new launches and replacements, we expect to progressively bridge the gap. Our Exports vertical recorded 79% YoY growth to ₹11 crore. We remain focused on long-term company level performance rather than quarterly and vertical wise fluctuations and are confident in the underlying growth opportunity in all three verticals.

Looking ahead, our priorities remain focused on strengthening strategic partnerships, expanding our offerings, achieving operational excellence, accelerating portfolio development, and driving disciplined execution. Supported by a modernized manufacturing base, a talented workforce, and a clear strategic direction, we are well positioned to capitalize on the opportunities across all three business verticals."

About Windlas Biotech Limited

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices ("GMP") with a focus on improved safety, efficacy and cost.

Safe Harbor

For More Information, Please Contact:

windlas	STELLAR
Windlas Biotech Limited CIN: U74899UR2001PLC033407 Ms. Komal Gupta Komal@windlasbiotech.com Contact no.: +91 124 2821034	**Stellar IR Advisors Pvt. Ltd.** Mr. Ankit Jain ankit@stellar-ir.com Mr. Manveer Sharma manveer@stellar-ir.com Contact no.: +91 22 62398024